Form 4 Filing for BioXcel Therapeutics, Inc.

Richard Steinhart, Chief Financial Officer of BioXcel Therapeutics, Inc., reported transactions involving Common Stock and Restricted Stock Units (RSUs). On May 4, 2026, 17,500 RSUs were granted, which were immediately disposed of (transaction code "D" under derivative table, but acquired under non-derivative table as "A"), with a reported price of $0.00. This is linked to acquiring 17,500 shares of Common Stock, bringing the total post-transaction shares to 33,145. This transaction was executed under a Rule 10b5-1 trading plan to cover taxes due upon vesting of RSUs. On May 20, 2026, 6,845 shares of Common Stock were sold at a weighted average price of $1.085 per share (ranging from $1.07 to $1.105), resulting in 26,300 shares remaining. The RSUs granted on January 1, 2026, vest over a two-year period, with 25% vesting on the six-month anniversary of November 4, 2025, and the remainder vesting in three equal installments every six months thereafter, contingent on continued employment.